Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50849 | 0.92 | MAPKAPK2 (0.40) | PARP1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL54971 | 0.91 | ALDH1A1 (0.35) | PARP1KIF11ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL2279943 | 0.89 | PARP1 (0.45) | PARP1KIF11ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3247853 | 0.88 | PARP1 (0.49) | PARP1KIF11ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL18661472 | 0.86 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2MEN1KMT2AMTNR1A | |
| SCHEMBL50557 | 0.86 | NR1I2 (0.49) | ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL18661422 | 0.85 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2MEN1KMT2AMTNR1A | |
| SCHEMBL2272736 | 0.84 | PARP1 (0.43) | PARP1KIF11ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5443018 | 0.83 | PARP1 (0.47) | PARP1KIF11ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2276592 | 0.83 | PARP1 (0.44) | PARP1KIF11ALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987038-B1 | HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-06 | — | — | EP | disclosed |
| EP-2029606-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-2029606-A2 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-03-04 | — | — | EP | disclosed |
| US-7456167-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456165-B2 | HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1987038-A2 | HCV NS5B INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007140254-A2 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070275947-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-29 | — | — | US | disclosed |
| WO-2007092888-A2 | HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185083-A1 | HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275947-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | PARP1 3234/4885KIF11 4447/4885ALDH1A1 1119/4885 |
| US-20070185083-A1 | HCV NS5B Inhibitors | EIF2AK2, HAVCR2, EIF5B | PARP1 3298/4885KIF11 4184/4885ALDH1A1 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.